Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of Adjunctive Cilostazol According to CYP2C19 Polymorphism
NCT00891670Phase 3
Key facts
- Status
- Unknown
- Start
- May 2009
- Primary completion
- Jun 2009
- Countries
- 1
- Sponsor
- Gyeongsang National University Hospital
- Modality
- Small Molecules
- Drugs
- cilostazol
- Conditions
- coronary artery stenosis
01
Overview
Phase 3, randomised trial of cilostazol in coronary artery stenosis (2 arms), sponsored by Gyeongsang National University Hospital. Primary endpoint: Reduction of maximal platelet aggregation at 30 days. Status: unknown.
02
Design
2 arms- Study design
- Randomized
triple group
received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
high maintenance dose group
received clopidogrel 150 mg/day with aspirin 100mg once daily
03
Who it enrols
Adults with significant coronary artery stenosis undergoing elective coronary stent implantation, excluding those with acute MI, bleeding diatheses, recent stroke, or severe organ dysfunction.
04
Endpoints
Primary
Reduction of maximal platelet aggregation
Secondary
Rate of high post-clopidogrel platelet reactivity
Beyond the preview
Go deeper on NCT00891670.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00891670.